South America Biguanide Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

High Type 2 Diabetes Prevalence

The South American biguanide market draws its largest treatment base from Type 2 diabetes, which represents most diagnosed and undiagnosed diabetes cases in the region. The IDF reported 35.4 million adults living with diabetes across South and Central America in 2024, with an age-standardized prevalence of 10.1%.^{[1]International Diabetes Federation, “IDF Diabetes Atlas, 11th Edition,” International Diabetes Federation, diabetesatlas.org} It projected prevalence to reach 11.5% by 2050, and it estimated that 30.4% of affected adults were undiagnosed.^{[2]“11th Edition of the IDF Diabetes Atlas: Global, Regional, and National Diabetes Prevalence Estimates for 2024 and Projections for 2050,” The Lancet Diabetes & Endocrinology, thelancet.com} This undiagnosed group can enter care as screening coverage improves in primary care and community settings. Diabetes-related health expenditure reached USD 81 billion in 2024, which reinforces the case for earlier treatment with affordable therapies. Urban growth, low physical activity, and rising obesity add to the patient base that requires long-term glucose management.

Continued First-Line Use of Metformin

Metformin remains the initial drug treatment in major South American diabetes pathways, which gives the South American biguanide market a durable base of demand. The Asociación Latinoamericana de Diabetes included metformin as initial pharmacotherapy for Type 2 diabetes in its 2025 standards of care.^{[3]Asociación Latinoamericana de Diabetes, “Standards of Care in Diabetes 2025,” Asociación Latinoamericana de Diabetes, aladlatam.org} Brazil’s SUS treatment guidance describes metformin as the treatment of choice for monotherapy and recommends extended-release metformin when gastrointestinal effects affect persistence. The guidance matters because public formularies continue to shape medicine use for patients who cannot pay for newer classes. Metformin’s established safety record also allows clinicians to use it across a broad range of early treatment settings. This role creates steady prescription volumes even when specialists select newer medicines for patients with elevated cardiovascular risk.

Affordable Genericization Across Public Health Systems

Genericization widens access to metformin products and supports volume demand in the South American biguanide market. ANVISA granted Eurofarma the first Brazilian generic registration for a dapagliflozin-metformin fixed-dose combination in May 2026. The registration required a minimum 35% price reduction against the reference product under Brazil’s generic medicine framework. State procurement for immediate-release and extended-release tablets has continued to support dispensing volumes in Brazil. Comparable tender systems in Colombia and Peru also make registered generic status important for formulary access. Volume-based procurement and demand for locally packaged, bioequivalent products favor suppliers that can meet quality requirements while supplying consistently at competitive prices.

Expanding Metformin Use in PCOS and Gestational Diabetes

Use beyond Type 2 diabetes broadens the treatment population for the South American biguanide market. A 2024 review of hospital-based studies in Brazil, Mexico, and Chile reported a pooled polycystic ovary syndrome prevalence of 30%, and the Brazilian sample recorded 40%. The 2025 ALEG consensus included metformin in evidence-based regional protocols for polycystic ovary syndrome care. It also identified cost and access as barriers to consistent use in secondary and tertiary care. In Brazil, the MevIP trial is comparing metformin and insulin for gestational diabetes, where the trial protocol cited an incidence range of 5% to 18%. A positive result could support future prescribing guidance and open a distinct care pathway for pregnant patients.

Price Controls and Tender-Driven Margin Compression

Tender-led purchasing holds medicine prices low, but it constrains supplier margins in the South American biguanide market. Suppliers must compete on price while maintaining product registration, bioequivalence, and continuous supply standards. This pressure is strongest in Brazil, Chile, Colombia, and Peru, where public purchasing represents a large share of demand. Argentina, Colombia, and Peru also face exposure to imported active pharmaceutical ingredients and foreign exchange movements. These costs can make it difficult for smaller suppliers to maintain pricing commitments across tender cycles. The result is a commercial environment that rewards scale, local packaging capacity, and stable procurement planning.

Increasing Competition from GLP-1 Receptor Agonists and SGLT-2 Inhibitors

Newer antidiabetic medicines can reduce metformin monotherapy use among patients with more complex clinical needs. Argentina’s 2025 SAD guidance prioritized GLP-1 receptor agonists and SGLT-2 inhibitors for high-risk patients regardless of HbA1c targets. These products remain much more expensive than generic metformin, so public formulary use of metformin remains broad. Manufacturers also face recurring work on nitrosamine risk assessment and batch testing. ANVISA’s RDC 677/2022 established requirements for risk assessment and corrective action for active ingredients and finished medicines. The burden is particularly important for extended-release products and can favor suppliers with established quality-control capacity.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

South America Biguanide Market Segment Analysis

Immediate-release tablets held 43.22% of the dosage-form segment in 2025, representing the largest component of the South American biguanide market for dosage forms. Public procurement in Brazil, Colombia, Chile, and Peru supports this format because buyers focus on low-cost registered generic products. Immediate-release tablets are familiar to prescribers and have an established supply base for high-volume public programs. The format remains important where medicine budgets are limited. It therefore provides the volume foundation for manufacturers participating in tenders.

Extended-release tablets are forecast to grow at a 4.25% CAGR through 2031, supported by tolerance benefits and wider generic availability. Brazil’s SUS guidance recommends the extended-release form when gastrointestinal effects affect treatment persistence. A Goiás state procurement record included metformin 850 mg extended-release tablets in the standard medicine list. Extended-release products typically carry unit prices that are 20% to 40% higher than immediate-release equivalents, which supports value where standard tablet prices are under tender pressure. Oral solutions retain a smaller stable role for pediatric and older patients who have difficulty swallowing tablets.

Monotherapy held 52.36% of the formulation-type segment in 2025, reflecting broad agreement that metformin is a suitable initial treatment for many people with Type 2 diabetes. This position accounts for the largest formulation contribution to the South American biguanide market. Standalone metformin is simple for public programs to procure and dispense. Its low cost is important in systems that manage large patient populations. Monotherapy will remain the core entry point even as combination treatment becomes more common for selected patients.

Fixed-dose combinations are forecast to expand at a 5.31% CAGR through 2031, the highest rate among formulation types. ANVISA approved Jardiance Duo, combining empagliflozin and metformin hydrochloride, in January 2026, and Eurofarma’s May 2026 generic registration widened the route for lower-cost dapagliflozin-metformin treatment. Single-tablet regimens can reduce pill burden and simplify pharmacy procurement. SAD’s 2025 guidance supports combination therapy from diagnosis for high-risk patients. These products bring the biguanide category closer to the broader oral antidiabetic treatment space.

Type 2 diabetes mellitus held 78.64% of the indication segment in 2025, which was the largest share in the South American biguanide market size by indication. The result reflects metformin’s continued clinical primacy in routine diabetes management. Public formularies and treatment protocols were designed around this use. Screening of undiagnosed adults can add more patients to this established pathway. This large treatment base gives the category more stability than its smaller emerging indications.

Polycystic ovary syndrome is expected to grow at a 4.76% CAGR through 2031. The 2025 ALEG consensus strengthened the regional basis for using metformin within evidence-based PCOS protocols, and a cited 2024 review found a 30% pooled clinical prevalence across its hospital-based South American samples. Prediabetes and gestational diabetes remain smaller parts of the indication mix. The Brazilian MevIP trial is evaluating metformin against insulin in gestational diabetes. If its primary objective is met, future clinical guidance could create a separate source of demand for pregnant women.

Hospital pharmacies held 45.25% of the distribution-channel segment in 2025, the largest South American biguanide market share across channels. Their lead reflects SUS tenders in Brazil, EsSalud procurement in Peru, and comparable institutional buying systems. Tender purchasing allows authorities to plan demand and purchase standard products at scale. Hospital pharmacy demand is less exposed to retail channel changes.

Online pharmacies are expected to grow at a 5.65% CAGR through 2031. A survey of 29 retail networks found digital medicine revenue reached BRL 20 billion (~USD 3.61 billion), and online sales represented 18% of Brazilian pharmaceutical retail. Retail pharmacies remain important for private-pay prescriptions in large cities. Digital platforms offer price visibility, electronic prescription integration, and home delivery.

Geography Analysis

Brazil Biguanide Market

Brazil held 54.42% of the South American biguanide market share in 2025 and remains the region’s central commercial geography. Its size reflects population, healthcare infrastructure, pharmaceutical purchasing power, and the scale of SUS coverage. The public system lists metformin in 500 mg and 850 mg formulations, creating consistent demand for registered suppliers. Farmácia Popular further supports patient access to metformin among eligible households. ANVISA’s 2026 decisions on Jardiance Duo and generic dapagliflozin-metformin products increase the availability of combination therapies. Brazil’s digital pharmacy retail also gives manufacturers another route to reach private-pay patients.

Argentina Biguanide Market

Argentina is projected to expand at a 6.17% CAGR from 2026 to 2031, the fastest rate in the South American biguanide market. Growth begins from a smaller base and is linked to recovering pharmaceutical spending volumes as macroeconomic conditions stabilize. The country recorded USD 2.5 billion in pharmaceutical imports during 2024, which shows its continued dependence on imported inputs. This dependence creates foreign exchange and supply-planning pressures for products using imported active ingredients. SAD’s 2025 guidance gives GLP-1 and SGLT-2 medicines a greater role for high-risk patients. Affordability constraints in public care nevertheless preserve metformin as the usual starting therapy for many newly diagnosed patients.

Broader South American Markets

Chile has a mature and stable environment where GES supports pharmacological treatment for Type 2 diabetes, including metformin. The country’s bioequivalence requirements narrow competition to suppliers that can meet technical registration standards. Colombia is the third-largest geographic contributor, supported by the SGSSS and procurement from INVIMA-registered suppliers. Combination treatments have room to grow in Colombia as treatment pathways add medicines when metformin alone does not achieve targets. Peru and the rest of South America account for smaller shares, with public procurement and fragmented private networks shaping local access. Ecuador and Uruguay have more developed pharmaceutical systems than Bolivia and Paraguay, where distribution and affordability gaps constrain generic metformin access in rural areas.